Research Roundup

Search Research Roundup


Mapping Bone Marrow Nerves

Mapping Bone Marrow Nerves—Stem cells in the bone marrow multiply and differentiate to form all the cells of the bloodstream—a process regulated by sympathetic nerves that infiltrate the marrow. With a three-year, $1.25 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases, Paul S. Frenette, M.D., will map those nerves to better understand their functions and physiology. In a three-stage experiment, Dr. Frenette and colleagues will define the marrow’s system of nerves, identify how those nerves relay signals and manipulate certain nerves to increase blood cell production (which could help reverse low blood cell counts in patients undergoing marrow-damaging chemotherapy). Dr. Frenette is professor of medicine and of cell biology and director of the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research at Einstein. (1U01DK116312-01)

Thursday, January 25, 2018
Modeling an Immune Response

Modeling an Immune Response—Tumor necrosis factor (TNF) binds to TNF receptors on cell surfaces, triggering signaling pathways that bolster the immune response. TNF acts to promote inflammation, which can sometimes lead to autoimmune disorders such as rheumatoid arthritis. Most previous studies have looked at the TNF binding process in the lab, which limits the usefulness of their findings. Yinghao Wu, Ph.D., was recently awarded a four-year, $1.3 million grant from the National Institutes of Health to simulate TNF binding to cell-surface receptors in vivo using computational modeling methods. Since drugs for some autoimmune diseases work by blocking TNF, the findings could potentially aid in developing more effective therapies. Dr. Wu is an assistant professor of systems & computational biology at Einstein. (1R01GM122804-01)

Friday, January 12, 2018
CAR T Therapy for Lymphoma Available at Montefiore/Einstein

CAR T Therapy for Lymphoma Available at Montefiore/Einstein—In results published online on December 10 in The New England Journal of Medicine, a type of immunotherapy called CAR-T cell therapy achieved impressive results in a phase 2 clinical trial involving 101 patients with large B-cell lymphomas that had not responded to other forms of treatment. Symptoms disappeared completely in 54 percent of patients, 82 percent had measurable improvement and more than half of patients survived 18 months after treatment. In CAR-T therapy, T cells are separated from a patient’s blood and are genetically engineered to produce receptors on their surfaces called chimeric antigen receptors, or CARs. These synthetic receptors allow the T cells to recognize and attach to a specific antigen on tumor cells—in this case, the CD19 antigen on B cells from which this type of lymphoma arises. After the modified T cells multiply in the laboratory, they are infused back into the patient to seek out and kill cancer cells bearing the CD19 antigen. Ira Braunschweig, M.D., associate professor of medicine at Einstein and director of the Stem Cell Transplant Program and clinical director of Hematologic Malignancies at Montefiore co-authored the NEJM paper and treated six of the patients in the CAR-T therapy trial. Montefiore is now an approved center of excellence for CART therapy and is one of the few such centers in the US to offer this treatment to patients with lymphoma and leukemia.

Tuesday, January 09, 2018
Following mRNA from Birth to Death

Following mRNA from Birth to Death—Messenger RNA (mRNA) is crucial for converting genetic information into proteins and for regulating gene expression. The life of an mRNA molecule in cells—including its transcription in the nucleus and translation of its message into a protein—can be followed using the MS2 imaging system, developed by Robert Singer, Ph.D., Evelina Tutucci Ph.D., and Maria Vera Ph.D., at Einstein. In a paper published online on November 13 in Nature Methods, Dr. Singer and colleagues describe re-engineering the MS2 system so that it can now follow mRNAs all the way from birth to degradation. Emerging evidence indicates that this final stage in the life of mRNA molecules is highly regulated: The need for rapid activation and de-activation of specific genes requires that mRNA production and degradation be coordinated so that protein levels can be tightly controlled. Dr. Singer is professor and co-chair of anatomy & structural biology, as well as co-director of the Gruss-Lipper Biophotonics Center and of the Integrated Imaging Program. He also is professor in the Dominick P. Purpura Department of Neuroscience and of cell biology and the Harold and Muriel Block Chair in anatomy & structural biology.

Tuesday, January 02, 2018
New Strategy for Treating Leukemia

New Strategy for Treating Leukemia—Acute myeloid leukemia (AML) is a devastating and hard-to-treat cancer of the blood and bone marrow. Defects in the transcription factor PU.1 are known to play a role in causing AML. But until now, all efforts at targeting AML caused by defective PU.1 have failed. Transcription factors—proteins that regulate gene expression by binding to DNA—have historically been very hard to target pharmacologically. Ulrich G. Steidl, M.D., Ph.D. and colleagues reported last October in the Journal of Clinical Investigation that they inhibited PU.1 through a novel strategy of targeting the minor groove—a part of the DNA double helix to which transcription factors don’t usually bind. The researchers’ first-in-class PU.1 inhibitors successfully halted overactive cell division in blood samples from AML patients, suggesting that targeting PU.1 could be a successful strategy for treating the disease. Dr. Steidl is the Diane and Arthur B. Belfer Faculty Scholar in Cancer Research, director of the Stem Cell Isolation and Xenotransplantation Facility and a professor of cell biology and of medicine at Einstein and associate chair for translational research in oncology at Montefiore.

Friday, December 29, 2017
Peripatetic mRNAs

Peripatetic mRNAs—In a study published online on October 24 in the Proceedings of the National Academy of Sciences, Einstein researchers, led by Robert Singer, Ph.D., describe the mechanism by which messenger RNA (mRNA) molecules travel from one cell to another: via extensions called membrane nanotubes that form when cells are in direct contact with each other. mRNA transfer from cell to cell could influence processes such as tissue development and cellular response to stress. Dr. Singer is professor and co-chair of anatomy & structural biology, as well as co-director of the Gruss-Lipper Biophotonics Center and of the Integrated Imaging Program. He also is professor in the Dominick P. Purpura Department of Neuroscience and of cell biology and the Harold and Muriel Block Chair in anatomy & structural biology. Gal Haimovich, the study’s lead author, was a Gruss Lipper Postdoctoral Fellow at Einstein when the research was conducted.

Wednesday, December 27, 2017
Hepatitis C Virus Can Infect Pancreatic Islet Cells

Hepatitis C Virus Can Infect Pancreatic Islet Cells—Up to 10 percent of patients with hepatitis C also have type 2 diabetes, but the association between the virus infection and diabetes is not well understood. A pilot study conducted by Yaron Tomer, M.D., and colleagues and published online on December 20 in Virology Journal found that HCV not only infects liver cells but can also infect in vitro pancreatic islet cells, including the cells that secrete insulin. The findings suggest that HCV infection of pancreatic islet cells alters the expression of pro-inflammatory cytokine proteins, which may contribute to the insulin deficiency that can lead to diabetes. Further research is needed to show whether curing hepatitis C can also improve or reverse type 2 diabetes. Dr. Tomer is the Anita and Jack Saltz Chair in Diabetes Research,  professor and chair of  medicine and is professor of microbiology & immunology.

Friday, December 22, 2017
Epigenetic Markers in Pancreatic Cancer

Epigenetic Markers in Pancreatic Cancer—Cancers sometimes start when external influences cause changes in DNA. These so-called epigenetic modifications can alter gene expression—silencing a gene or over-activating it, for example. In a study featured on the cover of the November issue of Genome Research, Amit Verma, M.B.B.S., reported that pancreatic cancers have unique epigenetic modifications in a regulatory portion of DNA known as Hydroxymethylcytosine (5-hmC). He and his team found that 5-hmC was abnormally distributed at locations in the genome that regulate the expression of several genes associated with cancer, such as the gene BRD4. Dr. Verma is professor of oncology and of developmental and molecular biology at Einstein and attending physician in oncology at Montefiore Einstein Center for Cancer Care. The study’s first author is Sanchari Bhattacharyya, Ph.D., a research associate in the department of medicine.

Friday, December 22, 2017
A Window into Cancer's Spread

A Window into Cancer's Spread—In a paper published November 28 online in Nature Methods, researchers describe a novel technique for permanently implanting a window into the chest wall of mice. Minimally invasive surgery allows mice to recover from surgery and anesthesia, breathe independently and live with the window for several weeks. Researchers can now repeatedly image the vasculature of the intact lung at single-cell resolution—converting the lung from sealed-off tissue observable only via fixed sections on slides to an accessible living organ. The windows should provide insight into many lung problems including asthma, acute sickle cell crisis and lung cancer. Using this new window the earliest processes involved in metastasis to the lung have been observed for the first time: tumor cells arriving in the lung, exiting from blood vessels (extravasation) and growing within the lung. This capability could revolutionize our understanding of cancer metastasis and its treatment. The study’s senior author is John Condeelis, Ph.D., professor and co-chair of anatomy and structural biology, and co-director of the Gruss Lipper Biophotonics Center and the Integrated Imaging Program. Co-first authors are David Entenberg, M.Sc., senior associate in anatomy & structural biology; and surgery resident Sonia Voiculescu, M.D.

Tuesday, December 19, 2017
Seeking Rejuvenation Factors in Blood

Seeking Rejuvenation Factors in Blood—For the last few decades, scientists studying aging have carried out heterochronic parabiosis—surgically creating a circulatory system shared by two animals of different ages. Those studies indicate that the blood of young animals contains rejuvenation factors (known as anti-geronic factors) that restore youthful characteristics to cells and tissues of older animals. Identifying these factors and finding how they exert their effects could lead to drugs for warding off age-associated diseases in people. The National Institute on Aging has awarded Yousin Suh, Ph.D., a four-year, $1.94 million grant to identify circulating anti-geronic factors using cultured cells and animal models of heterochronic parabiosis. Dr. Suh is professor of genetics, of ophthalmology & visual sciences, and of medicine.(1R01AG057433)

Monday, December 18, 2017
First Page | Previous Page | Page of 38 | Next Page | Last Page